best class
deliv one strongest quarter seen compani year
strong statement deliv long time highlight
includ organ day revenu growth oper margin expans
ep growth despit dilut deal also provid ep guidanc
street increas guidanc organ revenu growth
ep expect organ growth vs prior
earn vs prior trade around estim
syk market revenu growth appear durabl result provid us
even confid meet exceed oper margin
expans reiter buy rate
real soft spot syk quarter slower growth us knee market
caught investor attent us knee sale high-singl digit total global
rev grew robust solid mako placement procedur
strong cementless momentum syk mix drive growth syk us knee
growth clearli robust deceler versu along market
importantli pace syk share gain us knee show sign slow
outpac market point quarter similar us knee market
deceler price stabl volum weak last three year
us knee market growth usual fluctuat btw occasion growth slip
quarter littl wors last time growth dip
unusu disrupt market one major player
today suggest weak like temporari market growth
weak unpreced insid detail tabl mako syk organ
growth increas ep estim
ep estim
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
medic technolog compani
oper two busi segment orthoped
implant busi produc implant use joint
replac trauma spine craniomaxillofaci
surgic equip orthoped
hardwar well patient handl emerg
buy rate given top-tier
diversifi organ revenu growth outlook
balanc sheet capac believ one
best manag compani med-tech
tabl mako placement instal base procedur number -- -- mako total knee procedur grew sequenti
mako procedur applic
total surgeon train total knee
us knee market growth assum snn comp adj us knee growth flat sequenti
tabl us knee market growth trend adjust sell day weak
us knee cc growth adjust day
market growth adjust fx day
us knee market growth assum snn comp adj us knee growth flat sequenti
y/i organ ex fx
y/i organ ex fx
y/i organ ex fx
organ revenu growth adjust impact fx tailwind impact less sell day
price object assum trade ep estim
premium larg cap med-tech group premium believ justifi
given lead organ growth success track record also see
point ep upsid potenti well
upsid risk price object announc activ better
expect growth mako greater-than-expect impact share
loss consist strong earn growth given increasingli diversifi
downsid risk price object becom less confid execut
 econom impact surg busi lower capital-expenditure spend
wors anticip mako take market share expect
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
